Harvard Apparatus Regenerative Technology Inc

For the period ended Mar 31, 2024. Filed May 13, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 13, 2024

HRGNStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands, except share data)

	Series E Convertible Preferred	Number of Common Shares	Common	Additional Paid-in	Accumulated	Accumulated Other Comprehensive	Total Stockholders’
	Stock	Outstanding	Stock	Capital	Deficit	Loss	Equity
Balance at January 1, 2024	$—	13,947,324	$139	$93,463	$(91,956)	$—	$1,646
Share-based compensation	—	—	—	560	—	—	560
Net loss	—	—	—	—	(2,030)	-	(2,030)
Other comprehensive loss	—	—	—	—	—	(1)	(1)
Balance at March 31, 2024	$—	13,947,324	$139	$94,023	$(93,986)	$(1)	$175

	Series E Convertible Preferred	Number of Common Shares	Common	Additional Paid-in	Accumulated	Accumulated Other Comprehensive	Total Stockholders’
	Stock	Outstanding	Stock	Capital	Deficit	Loss	Deficit
Balance at January 1, 2023	$4,180	12,174,467	$122	$79,698	$(83,011)	$—	$(3,191)
Preferred stock dividends	80	—	—	(80)	—	—	(80)
Conversion of preferred stock for common stock	(209)	31,933	—	209	—	—	209
Issuance of common stock, net of offering costs	—	510,134	5	3,045	—	—	3,050
Share-based compensation	—	—	—	1,840	—	—	1,840
Net loss	—	—	—	—	(2,890)	—	(2,890)
Balance at March 31, 2023	$4,051	12,716,534	$127	$84,712	$(85,901)	$—	$(1,062)

See accompanying notes to unaudited condensed consolidated financial statements

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.